Patents Examined by Lynette Smith
  • RIP60 nucleic acid and polypeptide sequences and uses therefor
    Patent number: 6780986
    Abstract: The invention relates to nucleic acids and encoded polypeptides from the human zinc finger protein RIP60. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, fragments of the foregoing including functional fragments and variants. Kits containing the foregoing molecules additionally are provided.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: August 24, 2004
    Assignee: University of Vermont and State Agricultural College
    Inventors: Nicholas H. Heintz, Christopher R. Houchens
  • BASB019 proteins and genes from Moraxella catarrhalis, antigens, antibodies, and uses
    Patent number: 6764834
    Abstract: The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: July 20, 2004
    Assignee: SmithKline Beecham Biologicals, s.a.
    Inventor: Jean-Louis Ruelle
  • Multiple drug resistance gene atrD of aspergillus nidulans
    Patent number: 6746837
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus nidulans atrD are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: June 8, 2004
    Assignee: Stichting voor de Technische Wetenschappen
    Inventor: Maarten A. de Waard
  • Protein production in transgenic alfalfa plants
    Patent number: 5990385
    Abstract: This invention is directed to characterizing a host system suitable for the production of functional transgenic proteins, such as anti-human IgG, for use in applications requiring Government regulatory approval. It is well known that regulatory agencies required stable, consistent master cell banks and master cell lines for the production of transgenic proteins in order to ensure sufficient material for appropriate characterization, clinical trials, and potential sales. Current plant production systems require the establishment of seed banks for this purpose. However, there are many draw backs related to such a system for the production of a continuous reliable transgenic protein source. An aspect of this invention is directed to characterizing a plant production system suitable for transgenic proteins that meet the stringent regulatory requirements.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: November 23, 1999
    Assignees: Her Majesty the Queen in right of Canada, as represented by the Minister of Agriculture and Agri-Food, Canadian Red Cross Society, Universite Laval
    Inventors: Louis-P. Vezina, Serge Laberge, Renee Bazin, Habib Khoudi, Real Lemieux, Guy Allard
  • Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
    Patent number: 5562905
    Abstract: A chemically synthesized 15 amino acid peptide designated peptide 1-69, which has the sequence of amino acids numbers 308 to 322 (RIQRGPGRAFVTIGK) of the human immunodeficiency virus-1 (HIV-1) IIIB env-coded protein, was used to immunize animals. Peptide 1-69 elicited in immunized animals antibodies that block HIV proliferation and block HIV-induced cell fusion in cell culture.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: October 8, 1996
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: William R. Kenealy, Stephen R. Petteway, Paul J. Durda